Neoadjuvant Therapy for HER2-positive Breast Cancer

E-ISSN： 1876-1038|12|2|81-92

ISSN： 1574-8871

Source： Reviews on Recent Clinical Trials, Vol.12, Iss.2, 2017-05, pp. : 81-92

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Targeted Therapy in HER2-Positive Breast Cancer

Oncology Research and Treatment, Vol. 39, Iss. 5, 2016-04 ,pp. : 295-302

Karger

Access to resources Recommend Favorite

Trastuzumab as Single Agent Therapy for HER2-Positive Metastatic Breast Cancer

Oncology Research and Treatment, Vol. 33, Iss. 8-9, 2010-07 ,pp. : 420-421

Karger

Access to resources Recommend Favorite

Effect of adjuvant/neoadjuvant trastuzumab on clinical outcomes in patients with HER2‐positive metastatic breast cancer

CANCER, Vol. 120, Iss. 13, 2014-07 ,pp. : 1932-1938

John Wiley & Sons Inc

Access to resources Recommend Favorite

T-DM1 in the Neo-Adjuvant Treatment of HER2-Positive Breast Cancer: Impact of the KRISTINE (TRIO-021) Trial

Reviews on Recent Clinical Trials, Vol. 12, Iss. 3, 2017-11 ,pp. : 216-222

Bentham Science Publishers

Access to resources Recommend Favorite

Targeted Intraoperative Radiotherapy Tumour Bed Boost During Breast Conserving Surgery after Neoadjuvant Chemotherapy in HER2 Positive and Triple Negative Breast Cancer

Reviews on Recent Clinical Trials, Vol. 12, Iss. 2, 2017-05 ,pp. : 93-100

Bentham Science Publishers

Access to resources Recommend Favorite